

Author Index Volume 14 (2012)

Abraham, I. and J.L. Bootman, Why pharmacoeconomic policy should be transnational	(1)	7– 16
Abraham, I., see Olvey, E.L.	(1)	27– 35
Balbino, J.E., see de Labry Lima, A.O.	(2-4)	187–193
Barletta, J.F., see Patanwala, A.E.	(1)	93–104
Bootman, J.L. and G.H. Skrepnek, Achieving value: The role of pharmacoeconomics	(1)	3– 6
Bootman, J.L., see Abraham, I.	(1)	7– 16
Bootman, J.L., see Olvey, E.L.	(1)	69– 81
Cabezas, M.D., Current trend in pharmaceutical law in EU	(2-4)	195–207
Cheng, W., Y. Fang, D. Fan, J. Sun, X. Shi and J. Li, Study on the effect of “zero mark-up” policy on medicines in Beijing community health facilities	(2-4)	177–186
Chowdhury, N., Limits to the legal deliberation of science questions: A case study of borderline medical products in Europe	(2-4)	157–175
Cordoba-Diaz, D., see Quezada, M.S.	(2-4)	223–228
de Labry Lima, A.O., J.E. Balbino and J.R. Forns, Literature review on entry of medicines in European Small Markets	(2-4)	187–193
del Castillo Rodríguez, C., see Quezada, M.S.	(2-4)	223–228
Erstad, B.L., see Patanwala, A.E.	(1)	93–104
Fan, D., see Cheng, W.	(2-4)	177–186
Fang, Y., see Cheng, W.	(2-4)	177–186
Fishman, J.C. and G.H. Skrepnek, Pharmacoeconomic analyses of treatments for rare disease	(1)	51– 67
Forns, J.R., see de Labry Lima, A.O.	(2-4)	187–193
Li, J., see Cheng, W.	(2-4)	177–186
MacDonald, K., see Olvey, E.L.	(1)	27– 35
Mutebi, A., Patient-reported outcomes in the post-approval environment: Opportunities and challenges	(1)	83– 91

- Nevins, R., see Skrepnek, G.H. (1) 37– 49
- Olvey, E.L. and J.L. Bootman, The ‘fourth hurdle’ of pharmacogenomics (1) 69– 81
- Olvey, E.L., K. MacDonald and I. Abraham, Comparative effectiveness research: The translational science of comparing the what, how, when, in whom, by whom, and why of treatment effectiveness (1) 27– 35
- Olvey, E.L., see Skrepnek, G.H. (1) 105–122
- Palchik, V., see Real, J.P. (2-4) 209–222
- Palma, S.D., see Real, J.P. (2-4) 209–222
- Patanwala, A.E., J.F. Barletta and B.L. Erstad, Pharmacoepidemiology and patient safety in the critically ill (1) 93–104
- Quezada, M.S., C. del Castillo Rodríguez and D. Cordoba-Diaz, Pharmacist’s role in the studies of the veterinary-medicines-residues depletion (2-4) 223–228
- Real, J.P., V. Palchik, M. Salamano, M.L. Traverso and S.D. Palma, Off-label use of medicines in Argentina. Who wins and who loses? (2-4) 209–222
- Sahai, A., see Skrepnek, G.H. (1) 105–122
- Salamano, M., see Real, J.P. (2-4) 209–222
- Shi, X., see Cheng, W. (2-4) 177–186
- Skrepnek, G.H., E.L. Olvey and A. Sahai, Econometric approaches in evaluating costs and outcomes within pharmacoeconomic analyses (1) 105–122
- Skrepnek, G.H., R. Nevins and S. Sullivan, An assessment of health and work productivity measurement in employer settings (1) 37– 49
- Skrepnek, G.H., see Bootman, J.L. (1) 3– 6
- Skrepnek, G.H., see Fishman, J.C. (1) 51– 67
- Skrepnek, G.H., see Villa, L.A. (1) 17– 25
- Sullivan, S., see Skrepnek, G.H. (1) 37– 49
- Sun, J., see Cheng, W. (2-4) 177–186
- Traverso, M.L., see Real, J.P. (2-4) 209–222
- Valverde, J.L., Corporate responsibility and pharmaceutical fraud (2-4) 129–156
- Villa, L.A. and G.H. Skrepnek, Pharmacoeconomics and developing nations (1) 17– 25